Revelation Biosciences EBIT

The latest EBIT for REVB is $-15B as of June 2026. That compares with $-8.1M in the prior-year period — down 182891.8% year over year. That is below the sector sector average of $-26M. Investors often review this figure alongside Revelation Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, REVB's EBIT moved from $-8.1M to $-15B — a 182891.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Revelation Biosciences's operating scale or balance-sheet position.

Against its sector companies, REVB currently prints $-15B for EBIT, while the sector average sits near $-26M. That is roughly 57322.1% below the sector mean. Large gaps often invite a closer look at Revelation Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-15B for REVB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-26M. Explore the charts below for those layers of context.

After noting REVB's EBIT ($-15B), review year-over-year change from $-8.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.